Overdiagnosis of bone fragility in the quest to prevent hip fracture
- 26 May 2015
- Vol. 350 (may26 12), h2088
- https://doi.org/10.1136/bmj.h2088
Abstract
Despite widespread endorsement, Teppo Järvinen and colleagues argue that evidence for stratifying risk of fracture and subsequent drug therapy to prevent hip fracture is insufficient to warrant our current approachKeywords
This publication has 51 references indexed in Scilit:
- Low clinical relevance of a prevalent vertebral fracture in elderly men—the MrOs Sweden studyThe Spine Journal, 2015
- Conflicts at the heart of the FRAX toolCMAJ : Canadian Medical Association Journal, 2013
- Osteoporosis in the European Union: medical management, epidemiology and economic burdenArchives of Osteoporosis, 2013
- Fracture Risk Assessment: State of the Art, Methodologically Unsound, or Poorly Reported?Current Osteoporosis Reports, 2012
- Clinicians need to treat underlying osteoporosisBMJ, 2011
- Interpretation and use of FRAX in clinical practiceOsteoporosis International, 2011
- Estimates of the Proportion of Older White Women Who Would Be Recommended for Pharmacologic Treatment by the New U.S. National Osteoporosis Foundation GuidelinesJournal of Bone and Mineral Research, 2009
- Drugs for pre-osteoporosis: prevention or disease mongering?BMJ, 2008
- Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective?Bone, 2006
- Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO reportOsteoporosis International, 1994